Demand for leukemia therapeutics treatment will increase through 2036, with targeted drugs and immunotherapy at 60.0% of the treatment segment in 2026, driven by clinical adoption and regulatory compliance requirements. The market was valued at USD 17.40 billion in 2025 and is expected to be worth USD 35.15 billion by 2036.